The Clinical Evidence Platform for Animal Drug Development
Validated AI infrastructure replacing subjective scoring with objective, audit-ready clinical endpoints — deployed in active pharma programs since 2023.
Regulatory-Grade AI for Animal Health
OneKind AI builds infrastructure for AI-originated clinical endpoints in companion animal pharmaceutical development. The ORIGIN platform converts continuous behavioral data into validated, audit-ready evidence — deployed in active clinical programs with leading animal health companies since 2023.
Recurring Platform Revenue
Multi-year SaaS agreements with per-study pricing — delivering validated behavioral endpoints as a recurring service to pharma sponsors and CROs.
Recurring study revenue
Per-study platform fees under multi-year agreements with built-in renewals.
Pharma + CRO channels
Direct pharma sponsor engagements and CRO partnerships as distribution channels.
Multi-species expansion
Same pipeline and regulatory infrastructure extends across species and therapeutic endpoints.
Deployed. Validated. In Active Use.
The Market Is Moving Toward More Defensible Clinical Evidence
Animal health companies are under increasing pressure to generate clinical evidence that is more objective, reproducible, and operationally efficient. OneKind sits at the intersection of that shift: replacing subjective behavioral scoring with validated, audit-ready endpoints that can strengthen study design and accelerate development timelines.
Trusted in Active Clinical Programs
Published validation work conducted in collaboration with veterinary behavioral science experts across multiple countries. Research references available on request.
Recipient of Canada’s AI Compute Access Fund
OneKind AI was selected as one of 44 Canadian companies — from more than 1,300 applicants — in the first cohort of the AI Compute Access Fund — launched under Canada’s Sovereign AI Compute Strategy — administered by Innovation, Science and Economic Development Canada (ISED). Applications were assessed through a competitive process based on technical feasibility, commercialization potential, risk level, and anticipated benefits to Canada. View on Government of Canada Proactive Disclosure
Strategic Investors & Partners
Backed by investors with deep domain expertise in agriculture, animal health, and frontier technology commercialization.
Request Investment Materials
Detailed financial projections, cap table, platform roadmap, and regulatory strategy are available under NDA.
Specific questions about company financials? Reach David Dixon, CFO directly at [email protected].